Metformin exposure is associated with improved progression-free survival in diabetic patients after resection for early-stage non-small cell lung cancer

Metformin exposure in diabetic patients with early-stage non-small cell lung cancer may be associated with improved progression-free survival, but no effect was seen on overall survival. Further studies are warranted to evaluate if there is a therapeutic role for metformin in the treatment of non-small cell lung cancer.